GlaxoSmithKline hoping to improve COPD patient selection

GlaxoSmithKline is hoping to improve COPD patient selection with an Owlstone Medical's Breath Biopsy platform, which will analyze biomarkers from breath to produce data that can improve outcomes and cut costs, into its phase 2 trial of COPD candidate danirixin.

This platform will be used to evaluate the effects of danirixin on COPD and see if it can help with identifying the right patient for the right treatment.

Click here to view the entire article.